Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ -38.95MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
Sector
Industry
History
$ 1.23Close
$ 0.68 - $ 12.05 52-Week Range
Ticker Information
Ticker
CTXRCompany Name
CITIUS PHARMACEUTICALS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQCITIUS PHARMACEUTICALS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
CTXR - EBITDA Historical data
| Date | Depreciation, Amortization & Accretion | Earning Before Interest & Taxes (EBIT) | Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) |
|---|---|---|---|
| 6/30/2025 | $ 205.9K | $ -39.16M | $ -38.95M |
| 3/31/2025 | $ 217.38K | $ -41.23M | $ -41.01M |
| 12/31/2024 | $ 213.44K | $ -38.98M | $ -38.77M |
| 9/30/2024 | $ 209.61K | $ -38.56M | $ -38.35M |
| 6/30/2024 | $ 205.9K | $ -37.72M | $ -37.51M |
| 3/31/2024 | $ 202.06K | $ -35.62M | $ -35.42M |
| 12/31/2023 | $ 198.14K | $ -37.6M | $ -37.41M |
| 9/30/2023 | $ 194.32K | $ -31.97M | $ -31.77M |
| 6/30/2023 | $ 190.6K | $ -29.58M | $ -29.39M |
| 3/31/2023 | $ 186.93K | $ -30.11M | $ -29.92M |
Key Performance Insights, Last 5 Years
- CITIUS PHARMACEUTICALS INC's latest trailing twelve months (TTM) EBITDA stands at $ -17.38M.
- Over the past 5 years, CITIUS PHARMACEUTICALS INC's average EBITDA has been $ -30.23M.
- The median EBITDA for CITIUS PHARMACEUTICALS INC during this period was $ -30.18M
- CITIUS PHARMACEUTICALS INC reached its highest EBITDA over the past 5 years at $ -17.38M.
- The lowest EBITDA recorded by CITIUS PHARMACEUTICALS INC in the same timeframe $ -41.01M
Similar metrics to EBITDA:
- Depreciation, Amortization & Accretion - [Cash Flow Statement] A component of operating cash flow [NCFO] representing the aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a non-cash item, the net amount is added back to net income when calculating cash provided by operations.
- Enterprise Value over EBITDA - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest, taxes, depreciation, and amortization [EBITDA].
- EBITDA per Share - [Calculation] The amount of earnings before interest, taxes, depreciation, and amortization attributed to each share, calculated as [EBITDA] divided by the weighted average number of shares [SharesWA] after adjusting for [ShareFactor].
- Earning Before Interest & Taxes (EBIT) - [Income Statement] Earnings before interest and taxes measures a company's net income [NetInc] prior to the deduction of interest [IntExp] and tax expenses [TaxExp].
- EBITDA Margin - [Calculation] A company’s [EBITDA] as a percentage of [Revenue]. Measures how much earnings a company produces for each dollar of revenue generated before interest, taxes, depreciation and amortization.
Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].EBIT + DepAmor
(=) EBITDA EBITDA for CITIUS PHARMACEUTICALS INC is calculated as follows: EBIT [ $ -17.53M ] + DepAmor [ $ 152.36K ]
(=) EBITDA [ $ -17.38M ] CTXR - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years
$ -41.01M
Minimum
Mar 31, 2025
$ -17.38M
Maximum
Sep 30, 2020
$ -30.23M
Average
$ -30.18M
Median
EBITDA Benchmark AnalysisMarket
The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.9M with a standard deviation of $ 167.01M.
The following table provides additional summary stats:
EBITDA in the Market:
| filtered constituents | 3.24K |
|---|---|
| min | $ -493.3M |
| max | $ 590.6M |
| average | $ 58.9M |
| median | $ 8.92M |
| std | $ 167.01M |